Key Companies Covered in the Bone Growth Stimulators Market Research Report by Kenneth Research are Orthofix Medical, Inc., Bioventus LLC, DJO, LLC, Arthrex, Inc., Zimmer Biomet, Ember Therapeutics, Terumo Corporation, Stryker Corporation, Ossatec Benelux BV, Altis Biologics (Pty) Ltd, BTT Health GmbH, and other key market players.
New York, July 26, 2022 (GLOBE NEWSWIRE) -- There are 9 FDA-approved bone growth stimulators that are commercially available for the treatment of spinal fusion and fracture non-union, as of 2018 and this number is expected to increase on the back of increasing clinical studies based on bone growth stimulators. A survey study of orthopaedic surgeons found that 32% surgeons were using BGS. A more recent meta-analysis found that bone growth stimulator was effective in reducing non-union rate at 1 year for all indications—spinal fusion, osteotomies, fresh fractures, and non-union.
Kenneth Research has published a detailed market report on ‘Global Bone Growth Stimulators Market’ which includes the ongoing industry innovations and recent trends being adopted by the major industry players to achieve their business targets. Apart from that, the inclusive data on market size, growth rate, market revenue share, growth opportunities, and challenges for the market players along with a worldwide analysis on five major regions – North America, Latin America, Europe, Asia Pacific and Middle East & Africa has been provided in the report.
As per the World Health Organisation, approximately 1.71 billion people have musculoskeletal injuries worldwide and as the prevalence of musculoskeletal conditions varies by age and diagnosis, people of all ages everywhere around the world are affected. The global bone growth stimulators market was valued at approximately USD 1.5 billion by the end of 2021 and is projected to escalate at a CAGR of ~6% over the forecast period i.e., 2022–2030. The market growth can be attributed to the growing reluctance of patients towards involving any kind of foreign objects into their bodies across the world, and rising number of orthopaedic injuries is estimated to fuel the growth of the market. Further, growing healthcare expenditure across the world is expected to be a major factor to drive the market growth. According to The World Bank, in 2019, per capita health expenditure was USD 1121.97 and it is anticipated to increase significantly over the forecast period.
Get a Sample PDF of This Report @ https://www.kennethresearch.com/sample-request-10151518
In fact, between September 2015 to August 2018, total admissions of more than 10,900 patients were registered in the 3-year period, with increased average monthly admission of patients in the month of June, July and August. The death rate was about 0.55 per 100 admissions per year. This depicts the increasing prevalence of orthopaedic injuries, on the back of which, the global bone growth stimulators market is anticipated to grow in the upcoming years. Moreover, the rising disposable income amongst the global population is estimated to be a factor to fuel the market growth. According to The World Bank, disposable income per capita was USD 8784 in 2020.
Regionally, the global bone growth stimulators market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in the North America region is anticipated to hold the largest share by the end of the forecast period on the back of well-established healthcare infrastructure, efficient reimbursement policies, and increasing awareness about the new technology and treatment procedures in the region. In addition, the rising incidence of orthopaedic ailments in the region is expected to boost market growth. According to the National Spinal Cord Injury Statistical Centre (NSCISC), as of 2020, approximately 17,810 new cases of spinal cord injury are recorded every year in the United States.
Browse to access In-depth research report on Global Bone Growth Stimulators Market with detailed charts and figures: https://www.kennethresearch.com/sample-request-10151518
Further, the global bone growth stimulators market in the Asia Pacific region is projected to gain significant market share over the forecast period owing to rapidly rising geriatric population in the region. According to WHO, the proportion of people aged 60 or above in the region was 9.8% in 2017, and it is estimated to be increased to 13.7% by 2030. As aged people are more vulnerable to musculoskeletal injuries, this is expected to fuel the market growth significantly in the Asia Pacific region.
The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Get a Sample PDF of Global Bone Growth Stimulators Market @ https://www.kennethresearch.com/sample-request-10151518
The global bone growth stimulators market is segmented on the basis of product, into spinal fusion, delayed union, non-union bone fracture, maxillofacial surgery, and others, out of which, the spinal fusion segment is estimated to hold the largest market share over the forecast period owing to increasing number of spine related surgeries and the effectiveness of bone growth stimulators in them. The growing cases of accidents and sports injuries that cause spine-related issues is estimated to boost the market growth. As per the data by The World Health Organisation, approximately 1.3 million people die each year because of road traffic crashes. Between 20 to 50 million people suffer non-fatal injuries, with many incurring a disability as a result of their injury.
Further, the global bone growth stimulators market is segmented based on the end-use into hospital, homecare, and academic & research institutes. Out of these, the hospital segment is expected to hold a substantial market share over the forecast period on the back of increasing musculoskeletal injuries and increasing tendency to get treatment for the injuries among global population. According to the World Health Organization, 1.71 billion individuals worldwide suffer from musculoskeletal problems.
The global bone growth stimulators market is also segmented on the basis of product.
Global Bone Growth Stimulators Market; Segmentation by Product
Enquiry before Buying This Report @ https://www.kennethresearch.com/sample-request-10151518
Some of the prominent players and their company profiling mentioned in the report include Orthofix Medical, Inc., Bioventus LLC, DJO, LLC, Arthrex, Inc., Zimmer Biomet, Ember Therapeutics, Terumo Corporation, Stryker, Ossatec Benelux BV, Altis Biologics (Pty) Ltd, BTT Health GmbH, and others. The profiling enfolds growth opportunities, challenges, market trends, competitive analysis, and positioning, along with the strategies used by them to stay ahead of their competitors.
Sterilization Technology Market Analysis by Product Type (Chemical & Gas Sterilization, Filtration Sterilization, Ionizing Radiation Sterilization, and Thermal Sterilization); and by End User (Pharmaceuticals, Food & Beverages, Agriculture, Cosmetics, Manufacturing, Medical Devices, and Others)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Medical Nutrition Market Analysis by Product Type (Enteral, Oral Supplements, and Parenteral Nutrition); by End Users (Pediatric, and Adult Nutrition); and by Distribution Channels (Hospitals, Retail Pharmacies, and E-commerce Websites)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Disposable Syringes Market Segmentation by Type (General/Conventional, Safety, and Pre-Filled Syringes); by Syringe Tip (Luer-Lock, Slip, Eccentric, and Catheter Syringe Tips); by Application (Immunization, and Therapeutic Injections, and Others); by End-User (Hospitals, Diagnostic Laboratories, Blood Banks, Pharmaceutical Companies, and Others)-Global Demand Analysis & Opportunity Outlook 2021-2031
Cholera Vaccine Market Segmentation by Type (Killed, Whole-Cell Oral Cholera Vaccines, Other Oral Cholera Vaccines); by Product (Dukoral, Shanchol, Vaxchora, Euvichol, and Others)-Global Demand Analysis & Opportunity Outlook 2030
Carotid Artery Disease Market Segmentation by End-Users (Research and Academic Institute, Hospitals, Clinics, Ambulatory Surgical Centers, and Others); and by Application (Treatment, and Diagnosis)-Global Demand Analysis & Opportunity Outlook 2031
Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates, and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
Web: https://www.kennethresearch.com/
Investors are trying to make sense of the markets, in face of conflicting signals. Year-to-date, we’re facing deep losses – but more recently, a sharp rally despite this week’s confirmation that we’re in a recession. Government data released on Thursday showed a 0.9% GDP contraction in Q2, which came on the heels of a 1.6% contraction in Q1. That’s two quarters in a row, the definition of a recession. Jim Cramer, the well-known host of CNBC’s ‘Mad Money’ program, reminds us the ‘conventional wis
Looking to buy the dip? Start here.
How far off is The Boeing Company ( NYSE:BA ) from its intrinsic value? Using the most recent financial data, we'll...
Shares of the Illinois-based drugmaker AbbVie (NYSE: ABBV) were down by a hefty 5% as of 2:32 p.m. ET Friday afternoon. As a result, the Dividend Aristocrat's market capitalization has slipped by a staggering $13.2 billion today. Ahead of the opening bell, AbbVie announced its 2022 second-quarter earnings.
This has been a year to remember for investors in seemingly all the wrong ways. Since the major U.S. indexes hit their respective all-time closing highs between mid-November and the first week of January, the timeless Dow Jones Industrial Average, broad-based S&P 500, and growth-driven Nasdaq Composite (NASDAQINDEX: ^IXIC) have shed as much as 19%, 24%, and 34% of their value. You'll note by the drop in the S&P 500 and Nasdaq that both indexes have entered a bear market.
When Elon Musk decided to terminate his $44 billion deal to purchase Twitter the social-media company sued in the Delaware Court of Chancery. Twitter is suing for “specific performance,” a rare remedy that would require Musk to complete the merger. Unfortunately for Twitter, it isn’t Elon Musk Inc. but Elon Musk the individual who offered to buy the company.
Each of these five real estate investment trusts (REITs) currently pays a dividend of greater than 5%. For those willing to accept the risks, that’s a better yield than that of the U. S. Government 10-Year Treasury Note. Each REIT trades on the New York Stock Exchange, so plenty of information on these REITs is available from analysts at respected investment firms. Looking for ways to boost your returns? Check out Benzinga's coverage on Alternative Real Estate Investments: Exclusive Offering For
Warren Buffett energy favorite Occidental Petroleum is near a buy point, but earnings are due Tuesday. Check out this week's stocks to watch.
Apple delivered better-than-expected earnings and shares are now up 25% from the June low. Here's how to trade it from here.
A slowing economy is slowing ad spending. Long-term investors should use this weakness to pick up winners while they're on sale.
Alibaba Group Holding has been added to a growing list of Chinese companies that face potential delisting from US stock exchanges, days after the e-commerce giant announced plans to seek a primary listing on Hong Kong's bourse with the aim to diversify its investor base. The US Securities and Exchange Commission (SEC) on Friday included Alibaba, owner of the South China Morning Post, to its watch list of US-listed Chinese firms that face removal from American exchanges under a 2020 law, the Hold
Rio Tinto Group ( LON:RIO ) investors will be delighted, with the company turning in some strong numbers with its...
It is now guiding for third-quarter revenue of $15 billion-$16 billion vs. the $18.67 billion consensus. As for full-year 2022, its EPS expectation is now $2.30, down from its prior forecast of $3.60 and the $3.39 consensus. In terms of revenue for the year, Intel now expects $65 billion-$68 billion, down from $76 billion and well below the $74.4 billion consensus.
We feel now is a pretty good time to analyse Tilray Brands, Inc.'s ( NASDAQ:TLRY ) business as it appears the company...
Yahoo Finance markets reporter Alexandra Semenova details the losses Cathie Wood's ARK ETF is seeing amid Roku's earnings miss, Teledoc investments, and sale of Coinbase shares.
The company's future is in doubt after losing a key patent litigation
What do you do when you’re concerned that your holdings are down? Cash out for some alternatives? Buy the dip? Stash your cash under a mattress?
(Bloomberg) -- Investors should stay wary of US stocks and bonds as inflation remains a threat and recession looms, according to Rebecca Patterson, chief investment strategist at Bridgewater Associates.Most Read from BloombergThe Crypto Collapse Has Flooded the Market With Rolex and PatekShock July Stock Rally Was a Monster the Fed May Regret SeeingMeet the Russian Architect of Putin’s Economic CounterattackMonkeypox is Spreading Fast. Now Kids Are Getting It, TooThe stock market, which finished
We don’t advocate for theft. But stealing these strategies is a victimless crime.
See who joins GOOGL on this screen of Warren Buffett stocks based on the investing strategy of Berkshire Hathaway's CEO.